The development of BRAF inhibitors, together with the incorporation of MEK inhibitors (the main resistance mechanism), has made targeted therapy the standard treatment for patients with BRAF-mutated melanoma both in metastatic disease [10,11,12] and in the adjuvant scenario [13]. Here, BRAF is linked to melanoma.